Lack of response to botulinum toxin A in patients with hypertrophic pyloric stenosis
✍ Scribed by F. Heinen; V. Mall; K. D. Rückauer; P. Greiner; J. Sontheimer; M. Brandis; R. Korinthenberg
- Publisher
- Springer
- Year
- 1999
- Tongue
- English
- Weight
- 42 KB
- Volume
- 158
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Botulinum toxin type A (btx A) injections are the most effective treatment for most patients with focal dystonia. Some patients who improve after btx A injections and later lose response have serologic evidence of antibodies to btx A with the mouse neutralization assay (seropositive pat
originating from the peripheral rather than central retina. Correspondingly, VEP was also reported to be normal in MSA patients as it measures activity mainly originating from the central visual field. 7 Future studies will have to determine whether MSA patients show predominantly peripheral visual
## Abstract Fifteen patients with torticollis who had been treated with repeated injections of botulinum toxin type A (botox A) developed antibodies to the toxin. This resulted in loss of benefit in the 13 patients who had improved with botox A injections and failure to develop muscle atrophy after
## Abstract Between 1984 and 1992, 559 patients with torticollis were treated with botulinum toxin type A (btx) injections. Twenty‐four of these 559 patients (4.3%) had serological evidence of antibodies to btx by mouse neutralization assay. Some of the 559 patients had only one or two injection se